Patent covers a virus-like particle comprising a viral structural protein comprising modified envelope protein E3 Gaithersburg, Md. — May 18, 2018 — VLP Therapeutics, LLC. (“VLP”), a biotechnology company focusing on the research and development
“Structural studies of Chikungunya virus maturation” Moh Lan Yap, Thomas Klose, Akane Urakami, S. Saif Hasan, Wataru Akahata, and Michael G. Rossmann http://www.pnas.org/content/early/2017/11/29/1713166114.abstract?sid=89ef6c8b-994e-400d-af12-3726d0d40bbc
VLP Therapeutics Announces Phase 1 SBIR Grant Award From National Cancer Institute Grant will support development of novel Virus-Like Particle vaccine-based cancer immunotherapy October 6, 2017 Gaithersburg, MD – VLP Therapeutics, LLC (“VLP”), a biotechnology
“Envelope-modified tetravalent dengue virus-like particle vaccine: implication for flavivirus vaccine design” Akane Urakamia, Mya Myat Ngwe Tunb, Meng Ling Moib, Atsuko Sakuraia, Momoko Ishikawaa, Sachiko Kunoa, Ryuji Uenoa, Kouichi Moritab and Wataru Akahata http://jvi.asm.org/content/early/2017/09/21/JVI.01181-17.abstract
Vaccines are one of the most important inventions in the past centuries. The successful vaccines save millions of lives by eradicating the epidemic and pandemic diseases. I left the research field and formed VLP Therapeutics because I am committed to developing the next generation vaccine technology to treat the diseases that currently lack effective treatment. We believe that our i-αVLP vaccine technology has a potential to create a breakthrough treatments and make significant contributions to the improvement of global public health.